| Literature DB >> 34758820 |
Luuk H G A Hopman1, Mark J Mulder1, Anja M van der Laan1, Ahmet Demirkiran1, Pranav Bhagirath1, Albert C van Rossum1, Cornelis P Allaart1, Marco J W Götte2.
Abstract
BACKGROUND: Atrial fibrillation (AF) is associated with profound structural and functional changes in the atria. In the present study, we investigated the association between left atrial (LA) phasic function and the extent of LA fibrosis using advanced cardiovascular magnetic resonance (CMR) imaging techniques, including 3-dimensional (3D) late gadolinium enhancement (LGE) and feature tracking.Entities:
Keywords: Atrial fibrillation; Atrial fibrosis; Atrial remodeling; Atrial strain; Cardiovascular magnetic resonance (CMR)
Mesh:
Substances:
Year: 2021 PMID: 34758820 PMCID: PMC8582184 DOI: 10.1186/s12968-021-00820-6
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Fig. 1Left atrial (LA) strain during the 3 phases of the cardiac cycle. LA strain during the reservoir phase, conduit phase and contractile phase is illustrated, with corresponding two-chamber and four-chamber view, showing the LA endocardial and epicardial contours
Baseline characteristics of the study population
| AF patients (n = 94) | Healthy controls (n = 19) | ||
|---|---|---|---|
| Demographics | |||
| Age, years | 60 ± 9 | 58 ± 4 | 0.21 |
| Male gender | 60 (64%) | 11 (58%) | 0.63 |
| Weight (kg) | 84 ± 14 | 80 ± 12 | 0.44 |
| Height (cm) | 180 ± 11 | 176 ± 8 | 0.15 |
| BMI (kg/m2) | 25.9 ± 3.4 | 25.6 ± 5.1 | 0.84 |
| BSA (Mosteller)* | 2.0 ± 0.2 | 2.0 ± 0.2 | 0.48 |
| CHA2DS2-VASc score | 1.2 ± 1.2 | – | – |
| Hypertension | 30 (32%) | – | – |
| Diabetes mellitus | 4 (4%) | – | – |
| Medications | |||
| ACE inhibitor or ARB | 29 (30.9%) | – | – |
| Spironolactone | 3 (3.2%) | – | – |
| Amiodarone | 10 (11.0%) | – | – |
| Anticoagulation | 77 (81.9%) | – | – |
| AF history | |||
| Paroxysmal AF | 62 (66%) | – | – |
| Persistent AF | 32 (34%) | – | – |
| Time between AF diagnosis and CMR (months) | 32 (14–83) | – | – |
Values are expressed as number (percentage), mean ± SD or median (25–75th percentile). ACE angiotensin-converting-enzyme, ARB Angiotensin-receptor-blocker, AF atrial fibrillation, BMI body mass index, BSA body surface area, CHADSVASc history of congestive heart failure, hypertension, diabetes mellitus, stroke/transient ischemic attack/prior thromboembolism, vascular disease, age and sex, CMR cardiovascular magnetic resonance. *Calculated by the Mosteller method ((height (cm) x weight (kg)/3600)½)
CMR characteristics of the study population
| i | AF patients (n = 94) | Healthy Controls (n = 19) | |
|---|---|---|---|
| LA volume | |||
| LA volume—min (ml) | 50 ± 28 | 26 ± 11 | |
| LA volume—max (ml) | 100 ± 32 | 70 ± 15 | |
| LA volume index—max (ml/m2) | 49 ± 15 | 37 ± 8 | |
| LA sphericity (%)* | 79.5 ± 3.0 | ||
| LA function volumetric | |||
| Total LAEF (%) | 52 ± 13 | 64 ± 8 | |
| Passive LAEF (%) | 27 ± 10 | 33 ± 8 | |
| Active LAEF (%) | 25 ± 9 | 30 ± 7 | |
| LA strain | |||
| LA reservoir strain (%) | − 15.9 ± 3.8 | − 21.1 ± 3.6 | |
| LA conduit strain (%) | − 8.7 ± 2.7 | − 12.6 ± 2.5 | |
| LA contractile strain (%) | − 7.2 ± 2.3 | − 8.6 ± 2.2 | |
| LA peak positive strain rate | 0.72 ± 0.24 | 0.87 ± 0.16 | |
| LA peak early negative strain rate | − 0.82 ± 0.33 | − 1.22 ± 0.30 | |
| LA peak late negative strain rate | − 0.83 ± 0.30 | − 0.97 ± 0.26 | 0.5 |
| LA reservoir strain time (ms) | 392 ± 45 | 383 ± 35 | 0.39 |
| LA conduit strain time (ms) | 430 ± 131 | 354 ± 101 | |
| LA contractile strain time (ms) | 137 ± 41 | 123 ± 25 | 0.15 |
| LA LGE (n = 82) (%)* | 26.56 ± 16.0 | ||
| LV parameters | |||
| LV ESV (ml) | 69 ± 22 | 55 ± 12 | |
| LV EDV (ml) | 168 ± 42 | 146 ± 27 | |
| LVEF (%) | 59 ± 7 | 62 ± 5 | 0.08 |
Values are expressed as mean ± SD. AF atrial fibrillation, bpm beats per minute, CMR cardiovascular magnetic resonance imaging, EDV end diastolic volume, EF ejection fraction, ESV end systolic volume, LA left atrial; LAEF left atrial emptying fraction, LGE late gadolinium enhancement, LV left ventricular, LVEF left ventricular ejection fraction. Bold values denote statistical significance at the P < 0.05 level
*Not obtained in healthy volunteers due to the contrast agent dependency of the acquisition
Fig. 2LA phasic strain in atrial fibrillation patients and healthy controls. A LA reservoir strain, B LA conduit strain and C LA contractile strain are impaired in patients with atrial fibrillation (AF), as compared to healthy controls. AF atrial fibrillation, LA left atrial. Data are presented as bars with mean and SD
Patient characteristics stratified according to low and high extent of LGE
| Low (≤25.3%) LGE (n = 41) | High (>25.3%) LGE (n = 41) | ||
|---|---|---|---|
| Age, years | 59 ± 10 | 61 ± 7 | 0.42 |
| BSA (Mosteller)* | 2.1 ± 0.2 | 2.0 ± 0.2 | 0.15 |
| CHA2DS2-VASc score | 1.1 ± 1.2 | 1.3 ± 1.1 | 0.50 |
| Hypertension | 9 (22%) | 18 (44%) | |
| Diabetes mellitus | 2 (5%) | 2 (5%) | 1.00 |
| LA volume index—max (ml/m2) | 48 ± 12 | 51 ± 16 | 0.36 |
| LA sphericity (%) | 79.7 ± 2.8 | 79.3 ± 3.3 | 0.61 |
| LA function volumetric | |||
| Total LAEF (%) | 55 ± 11 | 50 ± 15 | 0.09 |
| Passive LAEF (%) | 29 ± 11 | 24 ± 9 | |
| Active LAEF (%) | 25 ± 9 | 25 ± 11 | 0.98 |
| LA strain | |||
| LA reservoir strain (%) | − 16.9 ± 3.3 | − 15.0 ± 3.9 | |
| LA conduit strain (%) | − 9.5 ± 2.6 | − 7.9 ± 2.7 | |
| LA contractile strain (%) | − 7.4 ± 2.4 | − 7.1 ± 2.3 | 0.55 |
| LA peak positive strain rate | 0.76 ± 0.27 | 0.70 ± 0.22 | 0.36 |
| LA peak early negative strain rate | − 0.89 ± 0.31 | − 0.76 ± 0.35 | 0.08 |
| LA peak late negative strain rate | − 0.88 ± 0.28 | − 0.80 ± 0.33 | 0.22 |
| LA reservoir strain time (ms) | 396 ± 51 | 383 ± 41 | 0.22 |
| LA conduit strain time (ms) | 452 ± 133 | 410 ± 130 | 0.15 |
| LA contractile strain time (ms) | 137 ± 35 | 132 ± 31 | 0.51 |
Values are expressed as number (percentage) or mean ± SD. BMI body mass index, BSA body surface area, CHA2DS2VASc history of congestive heart failure, hypertension, diabetes mellitus, stroke/transient ischemic attack/prior thromboembolism, vascular disease, age and sex, LA left atrium, LAEF left atrial emptying fraction, LGE late gadolinium enhancement. Bold values denote statistical significance at the P < 0.05 level
*Calculated by the Mosteller method ((height (cm) x weight (kg)/3600)½)
Fig. 3The association between the extent of LA late gadolinium enhancement and phasic LA strain in AF patients. A LA reservoir strain, B LA conduit strain and C LA contractile strain, stratified according to low and high degree of LA late gadolinium enhancement (LGE) in AF patients are depicted. LA left atrial, LGE late gadolinium enhancement. Data are presented as bars with mean and SD